|
WO2021051003A1
|
|
Ophthalmic formulations of methotrexate
|
|
WO2020223717A1
|
|
Process for preparation of aldehyde scavenger and intermediates
|
|
WO2020223685A1
|
|
Polymorphic compounds and uses thereof
|
|
WO2020198064A1
|
|
Ophthalmic formulations and uses thereof
|
|
WO2020118045A1
|
|
Injectable formulations
|
|
WO2020072621A1
|
|
Contact lens solutions and kits
|
|
CA3113462A1
|
|
Formulations for treatment of dry eye disease
|
|
AU2019319740A1
|
|
Polymorphic compounds and uses thereof
|
|
US2020038392A1
|
|
Topical compositions and methods of preparation and use
|
|
WO2020018498A1
|
|
Cyclodextrin formulations
|
|
AU2018348174A1
|
|
Treatment of inflammatory disorders
|
|
AU2018234919A1
|
|
Polymorphic compounds and uses thereof
|
|
CA3032609A1
|
|
Aldehyde trapping compounds and methods of use thereof
|
|
MX2019001722A
|
|
Aldehyde trapping compounds and uses thereof.
|
|
CA3022665A1
|
|
Combination treatment of ocular inflammatory disorders and diseases
|
|
AU2017224249A1
|
|
Treatment of allergic eye conditions with cyclodextrins
|
|
BR112018003264A2
|
|
aldehyde conjugates and uses thereof
|
|
KR20180073554A
|
|
Deuterated compounds and uses thereof
|
|
US2015335632A1
|
|
Toxic aldehyde related diseases and treatment
|
|
SG11201504859YA
|
|
Peri-carbinols
|
